Sign in
Taking people in United StatesPhase 2

Cancer Treatment Given at Home Compared With Clinic Visits

Tests cancer treatment given at home instead of in clinic, in adults with advanced cancer.

Key facts

Who runs it
Mayo Clinic
Where
Grand Forks and Jacksonville, United StatesSee the 2 sites
Trial code
Registry title
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Status
Recruiting
Phase
Phase 2
People taking part
220 people, planned
Started
21 Sept 2023
Expected to end
22 Mar 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Clinical Encounter
  • Home Health Encounter
  • Quality-of-Life Assessment
  • Questionnaire Administration
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced cancer who already get standard cancer drug treatment. It compares getting treatment at home with getting it in the clinic.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Advanced cancer of an accepted type, confirmed by tissue tests (liver cancer may be confirmed by imaging). Activity level (ECOG) of 0, 1 or 2.
Earlier treatment
Must be on a standard-of-care cancer drug regimen listed in the protocol, with good tolerance and no drug-related infusion reactions. The doctor must plan to continue it for at least 24 weeks.

Main reasons for not taking part

  • Receiving another investigational agent for the cancer
  • Needs help with daily living around the clock
  • Currently in hospital as an inpatient
  • Uncontrolled other illness, such as active infection, symptomatic heart failure, unstable angina, heart rhythm problem, heart attack within 6 months or wound healing disorder
  • Does not live in the area served by the home care team, or has no wifi at home

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Female or male patients with histologically confirmed malignancy. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis along; histologic confirmation is not required
  • Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) FDA-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. NCCN, ASCO, ASH, etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines; Note, patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Patients may receive any combination of any above listed medications or regimens:; Eligible disease cancer types:; Anal cancer; Appendiceal carcinoma; Basal cell carcinoma; Bladder cancer; Biliary cancer; Breast cancer; Central Nervous System malignancy including glioblastoma; Cervical cancer; Cholangiocarcinoma; Colorectal carcinoma; Endometrial cancer; Fallopian tube cancer; Gastroesophageal cancer [including gastric, esophageal, and gastroesophageal junction (GEJ) cancers]; Germ cell carcinoma; Head and Neck cancer; Hepatocellular Carcinoma; Liver; Lung; Lymphoma; Melanoma; Merkel Cell; Multiple Myeloma; Myelodysplastic syndrome; Myeloid Disorders; Neuroendocrine carcinoma; Ovarian cancer; Pancreatic adenocarcinoma; Penile carcinoma; Peritoneal carcinoma; Prostate cancer; Renal cell cancer; Sarcoma; Squamous cell Carcinoma of the Skin; Testicular cancer; Urethral carcinoma; Vaginal carcinoma; Vulvar carcinoma; Eligible Regimens; Fluorouracil (5-FU) +/- leucovorin +/- bevacizumab +/- trastuzumab; 5FU +/- leucovorin +/- bevacizumab +/- nivolumab; Atezolizumab +/- bevacizumab; Atezolizumab +/- bevacizumab + cobimetinib, atezolizumab +/- bevacizumab + vemurafenib, atezolizumab +/- bevacizumab + cobimetinib + vemurafenib; Avelumab; Avelumab + axitinib; Bevacizumab; Bevacizumab + capecitabine; Bevacizumab + irinotecan (+/- capecitabine); Bevacizumab + olaparib, bevacizumab + lenvatinib, bevacizumab + niraparib, bevacizumab + rucaparib; Bevacizumab + Temozolomide, Bevacizumab + Lomustine, or Bevacizumab + everolimus; Bevacizumab + trifluridine/tipiracil; Bortezomib; Bortezomib + cyclophosphamide, bortezomib + lenalidomide, bortezomib + pomalidomide, bortezomib + selinexor; Bortezomib + venetoclax; Carfilzomib; Carfilzomib + cyclophosphamide, carfilzomib + lenalidomide, carfilzomib + pomalidomide, carfilzomib + selinexor; Carfilzomib + venetoclax; Cemiplimab; Cisplatin; Cisplatin/5-FU; Cisplatin/etoposide; Cisplatin + durvalumab; Cisplatin + gemcitabine; Cisplatin + gemcitabine + durvalumab; Daratumumab (+ oral [PO] cyclophosphamide, lenalidomide, pomalidomide, or selinexor); Daratumumab + bortezomib (+ PO cyclophosphamide, lenalidomide, pomalidomide, or selinexor); Daratumumab + carfilzomib (+ PO cyclophosphamide, lenalidomide, pomalidomide, or selinexor); Degarelix; Durvalumab; Durvalumab + tremelimumab; Eribulin; FOLFIRI +/- bevacizumab (5FU +/- leucovorin + irinotecan); Fam-trastuzumab deruxtecan; Fulvestrant; Fulvestrant + ribociclib, fulvestrant + abemaciclib, fulvestrant + palbociclib, fulvestrant + alpelisib, or fulvestrant + capivasertib; Gemcitabine; Gemcitabine + durvalumab; Gemcitabine + paclitaxel protein-bound; Goserelin acetate; Irinotecan; Irinotecan + capecitabine; Lanreotide; Leuprolide; Nivolumab; Nivolumab + cabozantinib; Nivolumab-relatlimab; Octreotide; Paclitaxel; Pembrolizumab; Pembrolizumab + axitinib, pembrolizumab + lenvatinib, pembrolizumab + capecitabine, pembrolizumab + dabrafenib +/- trametinib, pembrolizumab + trametinib); Pemetrexed; Pertuzumab; Pemetrexed + pembrolizumab; Rituximab; Trastuzumab + paclitaxel; Trastuzumab with or without pertuzumab maintenance (SQ or IV) (+/- tucatinib +/- capecitabine); Decitabine; These regimens can be used only if patients are receiving one of the regimens above:; Darbepoetin-alfa; Epoetin; Filgrastim
  • Note: Female or male patients with histologically confirmed malignancy who are currently receiving treatment with one of the above eligible regimens may receive supportive care medications for treatment or prevention of bone metastases, including agents such as:; Zoledronic acid; Denosumab
  • Patient has had adequate tolerability of their clinical standard of care cancer treatment in the opinion of their treating physician and no drug-related infusion reactions prior to consent
  • Patients who according to documentation from their treating provider plan to continue the treatment regimen they are currently prescribed for at least 24 weeks from the start of cycle following randomization
  • Residing within the area serviced by supplier and paramedic network
  • Residence has wireless fidelity (wifi) to enable a reliable connection with the remote Command Center or it is suitable for connection through a wireless network solution
  • Age >= 18 years at time of registration
  • Signed informed consent form by patient
  • Willing and able to comply with the study protocol in the investigator's judgement
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2
  • Ability to complete questionnaire(s) by themselves or with assistance
  • RANDOMIZATION ELIGIBILITY CRITERIA: In addition to the criteria above, confirmation by the CCBW Command Center that the patient has adequate tolerability to the standard of care cancer therapy and no drug-related infusion reactions since pre-registration and prior to registration

Who cannot take part

  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm. Note: Patients are permitted concomitant standard of care oral drugs such as ribociclib, abemaciclib, or palbociclib in combination with endocrine therapy (e.g., Leuprolide, fulvestrant intramuscular [IM], etc.); tucatinib and capecitabine in combination with trastuzumab and pertuzumab for HER2 positive breast cancer; dexamethasone, cyclophosphamide, lenalidomide or pomalidomide for multiple myeloma; temozolomide, lomustine, or afinitor in combination with avastin for glioblastoma. In addition, all oral anti-hormonal agents for breast and prostate cancer are permitted (e.g., tamoxifen, arimidex, abiraterone, etc.) if used in combination with any of the drugs
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • Uncontrolled intercurrent illness including, but not limited to:; Ongoing or active infection; Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia; Myocardial infarction =< 6 months; Wound healing disorder; Or psychiatric illness/social situations that would limit compliance with study requirements
  • Requiring 24/7 assistance with activities of daily living (ADLs)
  • Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)

Where in United States

  • Altru Cancer CenterGrand Forks, United StatesContact: Alexis TatumTaking people
  • Mayo Clinic in FloridaJacksonville, United StatesContact: Clinical Trials Referral OfficeTaking people

About the trial

What the trial wants to find out

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings. This separation adds to the physical, emotional, social, and financial burden for patients and their families. The logistics and costs of navigating cancer treatments have become a principal contributor to patients' reduced quality of life. It is therefore important to reduce the burden of cancer in the lives of patients and their caregivers, and a vital aspect of this involves moving beyond traditional hospital and clinic-based care and evaluate innovative care delivery models with virtual capabilities. Providing cancer treatment at-home, versus in the clinic, may help reduce psychological and financial distress and increase treatment compliance, especially for marginalized patients and communities.

The 2 groups in the trial

  • Arm A (at-home treatment)Treatment being tested

    Patients continue receiving their SOC treatment regimen at home for approximately 24 weeks in the absence of disease progression or unacceptable toxicity. This includes drug administrations, injections/infusions and routine clinical laboratory tests in the home from the HHNP, overseen by Mayo Clinic's home health program CCBW Command Center. Patients are also provided biometric devices for health monitoring vital signs, as well as a computer tablet for video visits with the Mayo Clinic care team.

    Treatment: Home Health Encounter, Quality-of-Life Assessment, and Questionnaire Administration

  • Arm B (clinic & at-home treatment)Treatment being tested

    Patients continue receiving their SOC treatment regimen in the clinic for approximately 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then begin receiving their SOC treatment regimen at home as in Arm I for an approximate additional 16 weeks in the absence of disease progression or unacceptable toxicity.

    Treatment: Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment, and Questionnaire Administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cancer CARE Beyond Walls - A Pilot of a Randomized, Pragmatic Trial of Cancer Directed Therapy Administration in the Patients' Homes Versus in Clinic
Plain-language title
Cancer Treatment Given at Home Compared With Clinic VisitsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 November 2026